Jenburkt Pharmaceuticals Limited, a 40-year-old pharmaceutical organization listed on the Bombay Stock Exchange and a pioneer ...

"NIH-funded scientists are perennially expected to do more with less," writes one stakeholder. Another observer writes, "The current research funding system is due for reform, albeit in a more ...

Now, the people on the forefront of medical research across the Volunteer State are sounding the alarm, warning that their ...

In a visit to UB, the lawmakers said cutting indirect cost reimbursement for grants would negatively impact livesaving ...

Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

The impact will be crippling to biomedical research in the U.S., and institutions will immediately face hard choices about ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

Claiming the cuts are illegal, attorneys general from 22 states, including Rhode Island, on Monday sued the Trump administration, the Department of Health and Human Services, and the National ...

Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage ...